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Background: Limited knowledge exists on the association between intake of long-chained n-3 
polyunsaturated fatty acids (n-3 PUFAs) and risk of recurrence and all-cause mortality in 
patients with venous thromboembolism (VTE). 
Objectives: To investigate whether intake of marine n-3 PUFAs was associated with risk of 
recurrence and mortality in patients with incident VTE. 
Methods: A total of 595 patients with incident VTE and available data on n-3 PUFA intake 
were derived from the Tromsø Study surveys 4 (1994-95) and 6 (2007-08). Weekly intake of 
n-3 PUFAs was categorized as low, medium and high based on tertiles. Recurrent VTEs and 
all-cause mortality were registered up to December 31, 2016. Hazard ratios (HRs) were 
calculated using Cox-regression models with the low intake-category as reference. 
Results: There were 98 recurrent VTEs and 227 deaths during follow-up. Overall, we found 
no association between intake of n-3 PUFAs and risk of recurrent VTE. However, inverse 
associations were found for high intakes in patients with unprovoked VTE (HR 0.45, 95% CI 
0.20-1.01), cancer-free patients (HR 0.51, 95% CI: 0.27-0.95), and DVT patients (HR 0.49, 
95% CI: 0.24-0.97). The inverse associations were more evident when follow-up was 
restricted to the time after discontinuation of anticoagulant therapy. No association was 
observed between intake of n-3 PUFAs and mortality after incident VTE. 
Conclusions: A high dietary intake of marine n-3 PUFAs was associated with lower risk of 












Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is a common and burdensome disease associated with serious consequences 
(1, 2). The one- and eight-year mortality after VTE is 22-36% and 30-52%, respectively, with 
the highest rates observed after acute PE (3-6). Notably, patients with VTE have an elevated 
risk of mortality for up to three decades after the incident event when compared to the general 
population (7). Recurrent events are common, especially during the first year after the 
incident event, and the ten-year cumulative incidence of recurrence is 30-40% (4-6). The risk 
of recurrence is dependent on the etiology of the index event. The lowest risk is observed in 
patients with VTE provoked by a major transient risk factor (e.g., major surgery), an 
intermediate risk is observed in patients where a provoking factor cannot be identified, and 
the highest risk is recognized in presence of a major persistent risk factor (e.g., cancer) (8). 
Although anticoagulant therapy efficiently prevents VTE recurrence, such treatment is most 
often time-limited as the benefit must be balanced against the risk of bleeding (9, 10). In order 
to improve strategies for secondary prevention, there is a need to identify life-style factors that 
are inversely associated with adverse outcomes after VTE. 
 Fish and marine food products are advocated as important determinants of a healthy 
diet, and the long-chained n-3 polyunsaturated fatty acids (n-3 PUFAs; eicosapentaenoic acid 
(EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA)) are identified as key 
bioactive compounds (11-13). n-3 PUFAs are reported to be associated with downregulation 
of inflammation (14), platelet function (15), platelet endothelium-interactions (16, 17) and 
tissue factor expression (18), which are key pathways in the VTE pathogenesis. We and 
others have previously suggested a favorable association between dietary intake of fish and 
marine food products, particularly those high in n-3 PUFAs, and the risk of incident VTE (19-
22). Specifically, in our recent report based on the Tromsø Study, we found that moderate and 
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high intake of marine n-3 PUFA was associated with 22-26% lower risk of VTE (22). 
However, the role of n-3 PUFAs in relation to complications following VTE, such as 
recurrence and mortality, is largely unknown. 
 To our knowledge, only one study has investigated the association between n-3 
PUFAs and risk of recurrence and mortality after VTE. In the Swiss Cohort of Elderly 
Patients with Venous Thromboembolism (SWITCO65+), n-3 PUFA (marine- and plant-
based) levels in the erythrocyte membrane were measured in VTE patients aged ≥65 years, 
and the six-month and three-year risks of recurrence and mortality were investigated (23). 
They found that medium or high content of n-3 PUFAs in the erythrocyte membrane was 
associated with a lower six-month recurrence risk, and a lower risk of mortality at both time 
points. However, although, the fatty acid composition in the erythrocyte membrane reflects 
the fatty acid composition in the diet (24, 25), the association between dietary intake of n-3 
PUFAs and risk of recurrent VTE has not been studied. Further, whether the reported 
associations apply to VTE patients with a wider age-range and in a longer time-perspective, is 
not known. Finally, the plant-based and the marine-derived n-3 PUFAs may not be equally 
important in this context. Therefore, the aims of the present study was to investigate the 
association between dietary intake of marine n-3 PUFAs and the risk of recurrence and all-








The Tromsø Study is a population-based single-center cohort study with repeated health 
surveys of inhabitants of the Tromsø municipality in Norway (26). The study was approved 
by the Regional Committee for Medical and Health Research Ethics, and all participants 
provided written informed consent prior to inclusion. Patients with incident VTE were 
recruited among participants in the fourth (1994-95) and sixth (2007-08) surveys of the 
Tromsø study. The source population comprised of 29,538 unique individuals, of which 
10,304 took part in both surveys. The participants were followed from study inclusion to the 
end of the study period (December 31, 2016). All incident VTE events were identified and 
adjudicated by trained personnel searching the hospital discharge registry, the radiology 
procedure registry and the autopsy registry at the University Hospital of North Norway 
(UNN), as previously described in detail (27). UNN is the only hospital and the exclusive 
provider of relevant diagnostic radiology and hospital care in the study region, and manages 
essentially all in- and outpatients in Tromsø with a VTE diagnosis. Adjudication criteria for 
VTE were (i) signs and symptoms DVT or PE, (ii) objective confirmation by radiological 
procedures (compression ultrasonography, venography, spiral computed tomography, 
perfusion-ventilation scan or pulmonary angiography) or autopsy (only including cases where 
VTE was a significant contributor, or cause of death), (iii) a diagnosis of DVT or PE in the 
patient journal, and (iv) treatment initiation unless contraindications were specified. 
There were of 896 incident VTE events during follow-up, and these formed the basis 
of our study population. Participants (n=301) with incomplete information on n-3 PUFA 
intake were excluded, and 595 patients with incident VTE were included in the present study. 
A comparison of included VTE patients and those excluded due to incomplete data on fish 
intake and use of fish oil supplements is shown in Table S1.  
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 All VTE events were classified as provoked or unprovoked based on the presence of 
provoking factors at the time of diagnosis. Provoking factors were major surgery or trauma 
(within 8 weeks prior to the event), acute medical condition (acute myocardial infarction, 
acute ischemic stroke, major infectious disease), cancer, immobilization (bed rest ≥3 days or 
confinement to wheelchair, long distance travel ≥4 h. within the last 14 days) or a factor 
specifically described as provoking in the medical record, e.g. intravascular catheter. A VTE 




Information on anthropometry, dietary habits, physical activity and medical history was 
obtained from physical examinations and self-administered questionnaires at inclusion in 
Tromsø 4 or 6. Height, weight and blood pressure were measured by standardized procedures, 
as described elsewhere (27). Body mass index (BMI) was calculated as weight in kilograms 
divided by the square of height in meters (kg/m2). History of cardiovascular disease (CVD), 
diabetes, alcohol intake, physical activity, education level and smoking habits were reported 
via questionnaires. Information on cancer was obtained from the Cancer Registry of Norway. 
Active cancer was recorded when a cancer diagnosis was made in the time period from two 
years before to one year after the incident VTE event. Information on preplanned duration of 
anticoagulant treatment was obtained from the patients’ medical records. 
 
Assessment of marine n-3 PUFA intake  
The assessment of marine n-3 PUFA intake in the Tromsø Study has been described in detail 
previously (22, 28).  In brief, all participants in Tromsø 4 and 6 were asked to complete food 
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frequency questionnaires (FFQs), which included questions about how frequently they had fat 
fish and lean fish for dinner, how frequently they had fish as bread spread, and how often they 
used fish-oil supplements. In order to estimate the total intake of n-3 PUFAs, we first 
calculated the average content of n-3 PUFAs in different food items and supplements based 
on information obtained from official web resources (11, 29, 30), as previously described in 
detail (22). One serving unit of fish for dinner was defined as 200 g, and one serving unit of 
fish as bread spread was defined as 25 g. Total weekly intake of n-3 PUFAs was calculated by 
summarizing the amount of n-3 PUFAs derived from a person’s weekly intake of fat and lean 
fish, fish as bread spread and fish oil supplements. For participants with data on n-3 PUFAs 
intake in both Tromsø 4 and 6, the data with shortest proximity to the incident VTE event 
(before or after) was used, as it was assumed to be the most relevant intake. For the 
remaining, the available data, either from Tromsø 4 or 6, was used.  Eventually, there were 
342 and 253 participants with data form Tromsø 4 and 6, respectively. 
 
Outcome assessment  
All recurrent VTE events during follow-up were identified and adjudicated using the same 
procedure as described for the incident events. Data on mortality was obtained from the 
Norwegian Population Registry.  
 
Statistical analysis 
Person-years of follow were accrued from the date of the incident VTE to the date of 
recurrent VTE, death, migration or the end of the study period (December 31, 2016), 
whichever occurred first. Recurrent VTE was not included as a censoring event in the 
analyses on mortality. The study population was categorized into tertiles according to the 
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estimated intake of n-3 PUFAs. The ranges were <8.19, 8.19-29.1 and >29.1 g/week for low, 
medium and high intake, respectively. 
 Crude incidence rates of VTE recurrence (IRs) and mortality rates (MRs) according to 
n-3 PUFA intake were calculated and expressed as number of events per 100 person-years 
with 95% confidence intervals (CIs). Cox proportional hazards regression models were used 
to estimate hazard ratios (HRs) with 95% CIs for recurrence and mortality with the lowest 
tertile of n-3 PUFA intake as the reference. Calendar time was used as time scale for the 
recurrence analyses, and attained age was used as time scale in the mortality analyses. The 
analyses were performed in two models for VTE recurrence and two models for mortality. For 
recurrence, model 1 was unadjusted and model 2 was adjusted for age, sex and BMI. In 
addition, to account for death as a competing event to VTE recurrence, sub-distribution 
hazard ratios (SHR) were calculated according to the method by Fine and Gray (31). For 
mortality, model 1 included age (as time scale), while model 2 additionally included sex, 
BMI, systolic blood pressure and smoking. For both outcomes, sensitivity analyses excluding 
participants with active cancer at the time of incident VTE, were performed. Moreover, we 
performed sensitivity analysis where follow-up started at the time of discontinuation of 
anticoagulant treatment. IRs/MRs and HRs for recurrence and mortality according to n-3 
PUFA intake were calculated overall, and in subgroups stratified by characteristics of the 
incident event (unprovoked and provoked, DVT and PE). The proportional hazards 
assumption was evaluated and verified on the basis of Schoenfeld residuals. The cumulative 
incidence of VTE recurrence according to n-3 PUFA intake was visualized in 1-Kaplan-Meier 
plots. Statistical analyses were performed with STATA version 15.1 (Stata Corp, College 





RESULTS   
Characteristics of first and recurrent VTE according to categories of n-3 PUFAs intake are 
summarized in Table 1. Overall, the mean age at incident VTE was 67 (±13) years and 51% 
were men. Further, 38% of the incident VTE events were unprovoked and 58% presented as a 
DVT. The age at incident VTE increased with increasing intake of n-3 PUFAs. Likewise, the 
prevalence of CVD increased across tertiles, while the prevalence of cancer was lowest in the 
middle tertile. The mean age at recurrent VTE was 69 (±12) years, and 61% were men. 
 
Recurrence 
Among the 595 patients with incident VTE, there were 98 recurrences during a median 
follow-up of 3.6 years. HRs of recurrence according to n-3 PUFA intake are shown in Table 
2. Overall, there was no significant association between n-3 PUFA intake and risk of 
recurrence. Compared to the lowest tertile, the HR for tertile 2 was 1.09 (95% CI: 0.69-1.74) 
and the HR for tertile 3 was 0.77 (95% CI: 0.45-1.30) in the multivariable model (model 2). 
However, analyses stratified by characteristics of the incident event showed that a high n-3 
PUFA intake (i.e. tertile 3) was associated with a 55% lower recurrence risk after unprovoked 
VTE (HR model 2: 0.45, 95% CI 0.20-1.01), and a 51% lower risk after DVT (HR model 2: 
0.49, 95% CI 0.24-0.97). Further adjustment for alcohol consumption and physical activity 
did not affect our results (data not shown). 
The ten-year cumulative incidence of recurrence after VTE according to tertiles of n-3 
PUFA intake is shown in Fig. 1 and 2. The beneficial effect of a high n-3 PUFA intake on 
recurrence risk in patients with unprovoked VTE and DVT appeared to occur approximately 
two years after the incident event. 
11 
 
Sensitivity analyses excluding participants with active cancer (n=100) at the time of 
incident VTE are shown in Table 3. The results were comparable to the main analyses, but the 
inverse associations between n-3 PUFA intake and recurrence risk were stronger. Specifically, 
a high intake of n-3 PUFAs (tertile 3) was associated with a significant 49% lower risk of 
recurrence (HR model 2: 0.51, 95% CI: 0.27-0.95), which was most pronounced in those with 
unprovoked VTE (HR model 2: 0.41, 95% CI: 0.17-1.03) and DVT (HR model 2: 0.31, 95% 
CI: 0.13-0.71). However, in contrast to the main analyses, a high n-3 PUFA intake was also 
associated with a non-significant lower risk of recurrence after provoked VTE (HR: 0.66, 
95% CI: 0.27-1.57). We observed stronger inverse associations when start of follow-up was 
restricted to the period after discontinuation of anticoagulant treatment (Table S2). For high n-
3 PUFA intake we observed significantly reduced risk of recurrence after overall VTE (HR 
model 2: 0.42, 95% CI: 0.21-0.82), unprovoked VTE (HR model 2: 0.31, 95% CI: 0.12-0.83), 
and after DVT (HR model 2: 0.30, 95% CI: 0.13-0.73). Additionally, we observed a non-
significant reduced recurrence risk after provoked VTE and after PE in this analysis (HR 
model 2: 0.61, 95% CI: 0.24-1.55, and HR: 0.70, 95% CI: 0.24-2.04, respectively). In 
analyses taking competing risk by death into account, the SHRs were generally comparable to 
the HRs obtained from the Cox regression models (Tables 2 and 3). 
 
All-cause mortality 
There were 227 deaths during a median follow-up of 4.5 years. HRs of all-cause mortality 
according to n-3 PUFA intake are shown in Table 4. Overall, there was no association 
between intake of n-3 PUFAs and the risk of mortality after incident VTE in the multivariable 
model (HR tertile 2: 0.96, 95% CI: 0.69-1.35; HR tertile 3: 1.02, 95% CI: 0.73-1.43). 
Similarly, no association was observed between n-3 PUFA intake and mortality risk in 
analyses stratified by characteristics of the incident event. The results from the sensitivity 
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analyses restricted to participants without active cancer were generally comparable to the 
results from the main analyses (Table 5). However, a non-significant lower mortality risk was 




In the present study, we investigated the association between dietary intake of marine n-3 
PUFAs and the risk of VTE recurrence and all-cause mortality in patients with incident VTE 
recruited from a general population. We found that a high intake of n-3 PUFAs (upper tertile, 
>29.1 g/week) was associated with a lower recurrence risk compared to a low intake (lower 
tertile, <8.2 g/week) in patients with unprovoked incident events and in those with DVT. In 
contrast, there was no association between n-3 PUFAs intake and risk of mortality after 
incident VTE. The confidence intervals were wide, particularly in some subgroups, and our 
findings should therefore be interpreted with caution. 
We and others have previously reported on the association between fish or n-3 PUFA 
intake and the risk of incident VTE. Although findings have been inconsistent, the available 
data suggests that intake of n-3 PUFAs may lower the risk of incident VTE (19-21). In our 
previous report, we found an inverse association between intake of marine n-3 PUFAs and 
risk of VTE, while there was no association between total fish intake and VTE risk (22). 
Marine n-3 PUFAs have an impact on several molecular pathways and risk factors of 
relevance in the VTE pathogenesis. These include downregulation of inflammation (14), 
tissue-factor expression (18, 32), platelet function (15), platelet endothelium-interactions (16, 
17), and possibly hepatic excretion of coagulation factors (33). Moreover, n-3 PUFAs 




 To our knowledge, our study is among the first to explore the association between 
marine n-3 PUFAs and the risk of recurrence and mortality in patients with incident VTE. 
Reiner and colleagues investigated the association between levels n-3 PUFAs in the 
erythrocyte membrane, and the risk of recurrence and mortality in elderly VTE patients (23). 
Although there were few recurrent events (n=22), they found that a moderate or high level of 
n-3 PUFAs was associated with a 61-83% lower risk of recurrence and 66-71% lower risk of 
mortality at six months of follow-up. After three years, a moderate level was still associated 
with a 45% lower risk of mortality, while there was no association between n-3 PUFA levels 
and recurrence risk. As the fatty acid composition in the erythrocyte membrane reflects the 
diet (24, 25), these findings suggest that a medium or high dietary intake of n-3 PUFAs may 
be associated with a better prognosis after VTE, although the effect on recurrence risk 
appeared to be transient (23). Apparently conflicting, we found that a high dietary intake of n-
3 PUFAs was associated with 55% and 51% lower recurrence risk after unprovoked VTE and 
DVT, respectively, and that the effect occurred almost two years after the incident event. 
Although the different exposure assessments hamper a direct comparison of the studies, there 
are some plausible explanations for the diverging findings. First, the n-3 PUFA intake our 
study was high, and the upper tertile cut-off equals more than four grams per day, which is 
higher than the doses used in most clinical trials on prevention (34). Moreover, Reiner et al. 
(23) included PUFAs derived from both marine sources (i.e. EPA, DPA and DHA) and plants 
(i.e. alpha-linolenic acid, ALA) in their exposure variable. The impact of ALA in relation to 
health outcomes is less investigated and an effect is probably modest compared to marine-
derived n-3 PUFAs (35-37). Therefore, the association between n-3 PUFAs and recurrence 
risk may have been underestimated due to the inclusion of ALA in the study by Reiner et al. 
(23). Further, the patients included in SWITCO65+ were almost ten years older than those in 
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the present study (75 years vs. 67 years), and 29% of the patients had a history of previous 
VTE, while we exclusively included incident cases. 
The beneficial association of n-3 PUFAs on recurrence risk in our study was restricted 
to those with a high weekly intake, suggesting a mild protective effect of n-3 PUFA intake. 
Stratified analyses further revealed that the association was mainly driven by an effect in 
patients with unprovoked incident events. The risk of recurrence largely depends on the 
etiology of the incident event, which also reflects the underlying predisposition (baseline risk) 
for thrombosis (8, 38). Assuming a mild protective effect of n-3 PUFAs on VTE recurrence, it 
is plausible that the effect is most prominent in those with an intermediate recurrence risk, 
such as patients with unprovoked VTE. Conversely, a small effect may be difficult to observe 
in those with a low risk (e.g. VTE provoked by major surgery), and may be overwhelmed in 
those with a high risk (e.g. VTE provoked by active or progressive cancer). This is supported 
by our sensitivity analyses showing lowered risk estimates, even for provoked events, when 
patients with active cancer were excluded. 
We further observed a difference in the influence of n-3 PUFA intake on the risk of 
recurrence after DVT and PE. Apparently, a high intake was associated with a lower 
recurrence risk after DVT, and a higher risk of recurrence after PE. Although PE typically 
recur as a new PE and is regarded as a more severe form of VTE (39), the current guidelines 
for antithrombotic therapy do not distinguish between the two disease entities (9). However, 
in our data, which reflects clinical practice from 1994 to 2016, we found that 45% of patients 
with PE were scheduled anticoagulant treatment for ≥1 year, while this applied to only 13% 
of patients with DVT. The risk of recurrence is highest during the first year after incident 
VTE (4, 5), and 53% of the recurrences in the present study occurred during this period. 
Potentially, DVT patients receiving anticoagulant treatment for a shorter time-period may 
have benefitted more from a high intake of n-3 PUFAs, while an effect in patients with PE 
15 
 
may have been masked by long-term treatment. We addressed this point by restricting the 
follow-up time to the period after completion of anticoagulant treatment. Interestingly, this 
approach consistently showed inverse associations between high n-3 PUFA intake and 
recurrence after overall VTE and subtypes of VTE (unprovoked, provoked, DVT and PE).  
In contrast to the findings by Reiner and colleagues (23), we did not observe any 
association between n-3 PUFAs and the risk of mortality in patients with VTE. Although 
observational studies on the effect of n-3 PUFAs on cause-specific mortality in individuals 
without known CVD have shown somewhat diverging results  (40, 41), it may be suggested 
that marine-derived n-3 PUFAs are primarily associated with a lower risk of CVD-related 
death, while ALA is associated with a lower risk of death from non-CVD causes (36, 42). The 
most frequently reported causes of death in patients with VTE are cancer, PE, infections, and 
other cardiovascular or respiratory diseases (3, 43, 44). Potentially, a relatively higher 
proportion of deaths due to non-CVD causes in VTE-patients could explain the lack of a 
beneficial association between marine n-3 PUFAs and all-cause mortality in our study. 
Nevertheless, the results did not change after exclusion of patients with active cancer.  
The main strengths of our study include unselected VTE patients with a wide age 
distribution, a validated exposure variable, long follow-up and thoroughly validated 
outcomes. Limitations of the study include an observational design, which does not allow for 
random allocation to exposure groups, and residual confounding may be present. Further, a 
substantial proportion of participants were excluded due to incomplete information on n-3 
PUFA intake, and the included participants were younger and healthier compared to those 
excluded. This may influence the generalizability of our findings. Moreover, although we 
previously reported a significant trend between self-reported intake of marine n-3 PUFAs and 
serum concentrations (22), the correlation coefficients are generally reported to be low (45). 
Due to limited study power, the confidence intervals were wide, and our findings should 
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therefore be interpreted with caution. Finally, a long follow-up may introduce regression 
dilution as dietary habits may change over time. Such misclassification may influence the 
precision of our estimates, but is unlikely to be related the outcomes of the study, and would 
typically lead to an underestimation of the true association. 
In conclusion, a high intake of marine n-3 PUFAs was associated with a lower risk of 
VTE recurrence, which was most pronounced after unprovoked VTE and DVT, and in cancer-
free patients. In contrast, there was no association between n-3 PUFAs and the risk of all-
cause mortality in patients with incident VTE. 
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Figure 1 Ten-year cumulative incidence of recurrent venous thromboembolism (VTE) by 
tertiles of weekly intake of n-3 PUFAs for the total follow-up (Panel A) and follow-up 
restricted to the period after discontinuation of anticoagulant treatment (Panel B). Low intake: 
<8.19 g/week, medium intake: 8.19-29.1 g/week, and high intake: >29.1 g/week. PUFAs 




Figure 2 panel A-D. Cumulative incidence of recurrent venous thromboembolism (VTE) by 
tertiles of weekly intake of n-3 PUFAs according to the index event (A: unprovoked VTE, B: 
provoked VTE, C: Pulmonary embolism (PE), D: Deep vein thrombosis (DVT)). Low intake: 
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 TABLES AND FIGURES 
 
Table 1 Characteristics of patients with incident VTE (n=595) and recurrent events (n=98) according 
to tertiles of weekly intake of n-3 PUFAs. The Tromsø Study (1994-2016) 
n-3 PUFAs (g/week) All T1 (<8.19) T2 (8.19-29.1) T3 (>29.1) 
First VTE     
Number of patients 595 200 201 194 
   DVT 57.5 (342) 53.0 (106) 63.2 (127) 56.2 (109) 
   PE 42.5 (253) 47.0 (94) 36.8 (74) 43.8 (85) 
   Unprovoked 38.0 (226) 42.0 (84) 47.8 (96) 42.3 (82) 
Duration of anticoagulant treatment    
   < 3 months  20.0 (119) 31.9 (38)  37.0 (44) 31.1 (37) 
   3-6 months 42.5 (253) 30.4 (77) 35.2 (89) 34.4 (87) 
6-12 months 20.5 (122) 45.1 (55) 29.5 (36) 25.4 (31) 
   > 12 months 17.0 (101) 29.7 (30) 31.7 (32) 38.6 (39) 
Male sex 51.1 (304) 54.5 (109) 47.8 (96) 51.0 (99) 
Age at incident VTE 67 ± 13 63 ± 14 67 ± 13 71 ± 12 
BMI, kg/m2 27.4 ± 4.5 27.1 ± 4.3 27.4 ± 4.3 27.7 ± 4.4 
Diabetes 4.9 (29) 3.0 (6) 6.0 (12) 5.7 (11) 
History of CVD 13.1 (78) 7.5 (15) 14.4 (29) 17.5 (34) 
Cancer 16.8 (100) 18.0 (36) 13.9 (28) 18.6 (36) 
Current smoking 28.2 (168) 40.0 (80) 26.9 (54) 17.5 (34) 
Systolic BP, mmHg 142 ± 24 138 ± 23 142 ± 24 147 ± 25 
Second VTE (by index event):    
Number of patients  98 35 38 25 
   DVT 72.4 (71) 77.1 (27) 81.6 (31) 52.0 (13) 
   PE 27.6 (27) 22.9 (8) 18.4 (7) 48.0 (12) 
   Unprovoked 52.0 (51) 51.4 (18) 63.2 (24) 36.0 (9) 
Male sex 61.2 (60) 77.1 (27) 55.3 (21) 48.0 (12) 
Age at second VTE 69 ± 12 67 ± 13 69 ± 12 71 ± 12 
BMI, kg/m2 27.0 ± 4.5 27.1 ± 6.0 27.0 ± 3.3 26.8 ± 3.9 
Cancer 18.4 (18) 11.4 (4) 13.2 (5) 36.0 (9) 
Current smoking 20.4 (20) 31.4 (11) 23.7 (9) 20.0 (5) 
Systolic BP, mmHg 139 ± 20 135 ± 20 143 ± 20 139 ± 21 
25 
 
BMI body mass index, BP blood pressure, CVD cardiovascular disease (angina pectoris, stroke or myocardial 
infarction), DVT deep vein thrombosis, PE pulmonary embolism, PUFAs polyunsaturated fatty acids, T tertile, 
VTE venous thromboembolism. 





Table 2 Incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CI) for recurrent 
venous thromboembolism (VTE) by tertiles of weekly intake of marine n-3 polyunsaturated fatty acids 
(PUFAs). The Tromsø Study 1994-2016. 









HR (95% CI)† 
Model 2 
HR (95% CI)‡ 
SHR 
(95% CI)§ 
VTE       
T1 <8.19 1111 35 3.1 (2.3-4.4) Ref. Ref. Ref. 
T2  8.19-29.1 1080 38 3.5 (2.6-4.8) 1.10 (0.69-1.74) 1.09 (0.69-1.74) 1.19 (0.76-1.87) 
T3 >29.1 916 25 2.7 (3.7-4.0) 0.86 (0.51-1.43) 0.77 (0.45-1.30) 0.83 (0.49-1.42) 
Unprovoked VTE       
T1 <8.19 537 18 3.4 (2.1-5.3) Ref. Ref. Ref. 
T2  8.19-29.1 591 24 4.1 (2.7-6.1) 1.20 (0.65-2.21) 1.13 (0.61-2.10) 1.12 (0.61-2.08) 
T3 >29.1 448 9 2.0 (1.0-3.9) 0.59 (0.26-1.31) 0.45 (0.20-1.01) 0.42 (0.18-1.00) 
Provoked VTE       
T1 <8.19 575 17 3.0 (1.8-4.8) Ref. Ref. Ref. 
T2  8.19-29.1 487 14 2.9 (1.7-4.9) 0.96 (0.47-1.96) 1.00 (0.49-2.04) 1.10 (0.56-2.19) 
T3 >29.1 468 16 3.4 (2.1-5.6) 1.21 (0.60-2.43) 1.25 (0.61-2.56) 1.35 (0.70-2.61) 
PE       
T1 <8.19 540 8 1.5 (0.7-3.0) Ref. Ref. Ref. 
T2  8.19-29.1 378 7 1.9 (0.9-3.9) 1.18 (0.43-3.27) 0.97 (0.35-2.71) 1.10 (0.41-2.95) 
T3 >29.1 405 12 3.0 (1.7-5.2) 1.93 (0.78-4.75) 1.55 (0.62-3.87) 1.64 (0.65-4.12) 
DVT       
T1 <8.19 571 27 4.7 (3.2-6.9) Ref. Ref. Ref. 
T2  8.19-29.1 703 31 4.4 (3.1-6.3) 0.94 (0.56-1.57) 1.00 (0.59-1.69) 1.12 (0.67-1.86) 
T3 >29.1 511 13 2.5 (1.5-4.4) 0.54 (0.28-1.06) 0.49 (0.24-0.97) 0.54 (0.27-1.08) 
CI confidence interval, DVT deep vein thrombosis, PE pulmonary embolism, SHR subdistribution hazard ratio,  
T tertile. 
*Per 100 person-years 
†Unadjusted 
‡Adjusted for age, sex and body mass index 




Table 3 Incidence rates (IRs) and hazard ratios (HRs) for recurrent venous thromboembolism (VTE) 
by tertiles of weekly intake of marine n-3 polyunsaturated fatty acids (n-3 PUFAs) after excluding 
individuals with active cancer. The Tromsø Study 1994-2016 









HR (95% CI)† 
Model 2 
HR (95% CI)‡ 
SHR 
(95% CI)§ 
VTE       
T1 <8.19 1026 31 3.0 (2.1-4.3) Ref. Ref. Ref. 
T2  8.19-29.1 1005 33 3.3 (2.3-4.6) 1.07 (0.65-1.74) 1.01 (0.61-1.66) 1.09 (0.67-1.77) 
T3 >29.1 826 16 1.9 (1.2-3.2) 0.64 (0.35-1.17) 0.51 (0.27-0.95) 0.56 (0.30-1.03) 
Unprovoked VTE       
T1 <8.19 524 16 3.1 (1.9-5.0) Ref. Ref. Ref. 
T2  8.19-29.1 570 21 3.7 (2.4-5.7) 1.20 (0.62-2.29) 1.13 (0.59-2.18) 1.15 (0.60-2.22) 
T3 >29.1 407 7 1.7 (0.8-3.6) 0.55 (0.23-1.34) 0.41 (0.17-1.03) 0.38 (0.15-1.00) 
Provoked VTE       
T1 <8.19 502 15 3.0 (1.8-5.0) Ref. Ref. Ref. 
T2  8.19-29.1 433 12 2.8 (1.6-4.9) 0.92 (0.43-1.96) 0.88 (0.40-1.90) 0.97 (0.47-2.04) 
T3 >29.1 419 9 2.1 (1.1-4.1) 0.76 (0.33-1.77) 0.66 (0.27-1.57) 0.79 (0.36-1.73) 
PE       
T1 <8.19 500 8 1.6 (0.8-3.2) Ref. Ref. Ref. 
T2  8.19-29.1 346 6 1.7 (0.8-3.9) 1.02 (0.35-2.96) 0.75 (0.26-2.18) 0.91 (0.33-2.52) 
T3 >29.1 354 8 2.3 (1.3-4.5) 1.35 (0.50-3.62) 0.99 (0.36-2.71) 1.07 (0.41-2.81) 
DVT       
T1 <8.19 526 23 4.4 (2.9-6-6) Ref. Ref. Ref. 
T2  8.19-29.1 660 27 4.1 (2.8-6.0) 0.93 (0.53-1.63) 0.98 (0.55-1.73) 1.04 (0.60-1.81) 
T3 >29.1 472 8 1.7 (0.8-3.4) 0.39 (0.17-0.88) 0.31 (0.13-0.71) 0.35 (0.15-0.81) 
CI confidence interval, DVT, deep vein thrombosis, PE pulmonary embolism, SHR subdistribution hazard ratio, 
T tertile. 
*Per 100 person-years 
†Unadjusted 
‡Adjusted for age, sex and body mass index 




Table 4 Mortality rates (MRs) and hazard ratios (HRs) for all-cause mortality across tertiles of weekly 
intake of marine n-3 polyunsaturated fatty acids (n-3 PUFAs). The Tromsø Study 1994-2016. 





Crude MR (95% 
CI)* 
Model 1 
HR (95% CI)† 
Model 2 
HR (95% CI)‡ 
VTE      
T1 <8.19 1302 72 5.5 (4.4-7.0) Ref. Ref. 
T2  8.19-29.1 1220 76 6.2 (5.0-7.8) 0.97 (0.70-1.34) 0.96 (0.69-1.35) 
T3 >29.1 1033 79 7.6 (6.1-9.5) 1.01 (0.72-1.40) 1.02 (0.73-1.43) 
Unprovoked VTE      
T1 <8.19 658 17 2.6 (1.6-4.2) Ref. Ref. 
T2  8.19-29.1 682 24 3.5 (2.4-5.3) 1.11 (0.59-2.08) 1.08 (0.56-2.10) 
T3 >29.1 510 26 5.1 (3.5-7.5) 1.26 (0.68-2.35) 1.26 (0.67-2.36) 
Provoked VTE      
T1 <8.19 644 55 8.5 (6.6-11.1) Ref. Ref. 
T2  8.19-29.1 537 51 9.5 (7.2-12.5) 0.98 (0.66-1.44) 1.02 (0.69-1.52) 
T3 >29.1 523 53 10.1 (7.7-13.3) 0.91 (0.61-1.35) 0.94 (0.62-1.42) 
PE      
T1 <8.19 586 29 4.9 (3.4-7.1) Ref. Ref. 
T2  8.19-29.1 403 23 5.7 (3.8-8.6) 0.95 (0.54-1.68) 0.95 (0.53-1.68) 
T3 >29.1 457 35 7.7 (5.5-10.7) 1.21 (0.73-2.02) 1.16 (0.69-1.96) 
DVT      
T1 <8.19 716 43 6.0 (4.5-8.1) Ref. Ref. 
T2  8.19-29.1 818 53 6.5 (5.0-8.5) 0.95 (0.63-1.44) 0.98 (0.64-1.49) 
T3 >29.1 575 44 7.6 (5.7-10.3) 0.87 (0.56-1.35) 0.94 (0.60-1.48) 
CI confidence interval, DVT deep vein thrombosis, PE pulmonary embolism, T tertile. 
*Per 100 person-years 
†Adjusted for age (as time-scale) 






Table 5 Mortality rates (MRs) and hazard ratios (HRs) for all-cause mortality by tertiles of weekly 
intake of marine n-3 polyunsaturated fatty acids (n-3 PUFAs) excluding individuals with active 
cancer. The Tromsø Study 1994-2016. 








HR (95% CI)† 
Model 2 
HR (95% CI)‡ 
VTE      
T1 <8.19 1203 43 3.6 (2.7-4.8) Ref. Ref. 
T2  8.19-29.1 1138 53 4.7 (3.6-6.1) 1.03 (0.68-1.55) 1.00 (0.66-1.51) 
T3 >29.1 921 51 5.5 (4.2-7.3) 0.96 (0.63-1.45) 0.91 (0.60-1.40) 
Unprovoked VTE      
T1 <8.19 631 14 2.2 (1.3-3.7) Ref. Ref. 
T2  8.19-29.1 653 17 2.6 (1.6-4.2) 0.95 (0.46-1.95) 0.92 (0.43-1.97) 
T3 >29.1 456 22 4.8 (3.2-7.3) 1.34 (0.68-2.64) 1.28 (0.64-2.57) 
Provoked VTE      
T1 <8.19 572 29 5.1 (3.5-7.3) Ref. Ref. 
T2  8.19-29.1 483 35 7.3 (5.2-10.1) 1.09 (0.66-1.80) 1.04 (0.62-1.74) 
T3 >29.1 465 29 6.2 (4.3-9.0) 0.75 (0.43-1.29) 0.68 (0.39-1.20) 
PE      
T1 <8.19 546 18 3.3 (2.1-5.2) Ref. Ref. 
T2  8.19-29.1 368 14 3.8 (2.3-6.4) 0.88 (0.42-1.83) 0.86 (0.41-1.80) 
T3 >29.1 401 23 5.7 (3.8-8.6) 1.33 (0.71-2.51) 1.21 (0.63-2.30) 
DVT      
T1 <8.19 657 25 3.8 (2.6-5.6) Ref. Ref. 
T2  8.19-29.1 770 39 5.1 (3.7-6.9) 1.05 (0.63-1.76) 1.11 (0.66-1.88) 
T3 >29.1 520 28 5.4 (3.7-7.8) 0.75 (0.43-1.31) 0.80 (0.45-1.41) 
CI confidence interval, DVT deep vein thrombosis, PE pulmonary embolism, T tertile. 
*Per 100 person-years 
†Adjusted for age (as time-scale) 




Figure 1 Ten-year cumulative incidence of recurrent venous thromboembolism (VTE) by tertiles of 
weekly intake of n-3 PUFAs for the total follow-up (Panel A) and follow-up restricted to the period 
after discontinuation of anticoagulant treatment (Panel B). Low intake: <8.19 g/week, medium intake: 
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Figure 2 panel A-D. Cumulative incidence of recurrent venous thromboembolism (VTE) by tertiles of 
weekly intake of n-3 PUFAs according to the index event (A: unprovoked VTE, B: provoked VTE, C: 
Pulmonary embolism (PE), D: Deep vein thrombosis (DVT)). Low intake: <8.19 g/week, medium 
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Table S1 Comparison of included and excluded VTE-patients 
 Included (n=595) Excluded (n=304) 
  
Incident VTE    
     DVT 57 (342) 62 (187) 
     PE 43 (253) 38 (117) 
     Unprovoked 44 (262) 41 (124) 
Male sex 51 (304) 42 (129) 
Age at incident VTE 67 ± 13 71 ± 13 
Body mass index, kg/m2 27.4 ± 4.5 27.1 ± 4.5 
Diabetes 5 (29) 3 (10) 
History of CVD 13 (78) 18 (55) 
Cancer 17 (100) 16 (48) 
CVD cardiovascular disease (angina pectoris, stroke or myocardial infarction), DVT deep vein thrombosis, PE 
pulmonary embolism, VTE venous thromboembolism. 

















Table S2  
Incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CI) for recurrent venous 
thromboembolism (VTE) by tertiles of weekly intake of marine n-3 polyunsaturated fatty acids 
(PUFAs) in sensitivity analyses with follow-up restricted to the period after discontinuation of 
anticoagulant therapy. The Tromsø Study 1994-2016. 









HR (95% CI)† 
Model 2 




T 1 935 31 3.3 (2.3-4.7) Ref. Ref. Ref. 
T 2 927 32 3.5 (2.4-4.9) 1.03 (0.63-1.69) 0.99 (0.60-1.63) 1.03 (0.62-1.68) 
T 3 747 13 1.7 (1.0-3.0) 0.53 (0.28-1.02) 0.42 (0.21-0.82) 0.48 (0.25-0.94) 
Unprovoked VTE 
T 1 425 15 3.5 (2.1-5.9) Ref. Ref. Ref. 
T 2 502 22 4.4 (2.9-6.7) 1.24 (0.64-2.40) 1.14 (0.58-2.23) 1.18 (0.61-2.30) 
T 3 361 6 1.7 (0.7-3.7) 0.48 (0.19-1.25) 0.31 (0.12-0.83) 0.33 (0.12-0.89) 
Provoked VTE 
T 1 511 16 3.1 (1.9-5.1) Ref. Ref. Ref. 
T 2 424 10 2.4 (1.3-4.4) 0.76 (0.34-1.68) 0.79 (0.35-1.77) 0.77 (0.35-1.69) 
T 3 386 7 1.8 (0.9-3.8) 0.63 (0.26-1.56) 0.61 (0.24-1.55) 0.69 (0.29-1.64) 
PE 
T 1 415 8 1.9 (1.0-3.9) Ref. Ref. Ref. 
T 2 294 6 2.0 (0.9-4.5) 1.02 (0.35-2.95) 0.67 (0.23-1.95) 0.74 (0.26-2.15) 
T 3 321 6 1.9 (0.8-4.2) 0.99 (0.34-2.87) 0.70 (0.24-2.04) 0.82 (0.29-2.32) 
DVT 
T 1 521 23 4.4 (2.9-6.6) Ref. Ref. Ref. 
T 2 634 26 4.1 (2.8-6.0) 0.92 (0.53-1.62) 0.99 (0.56-1.76) 1.11 (0.63-1.95) 
T 3 426 7 1.6 (0.8-3.4) 0.38 (0.16-0.88) 0.30 (0.13-0.73) 0.36 (0.15-0.86) 
CI confidence interval, DVT deep vein thrombosis, PE pulmonary embolism, SHR subdistribution hazard ratio,  
T tertile. 
*Per 100 person-years 
†Unadjusted 
‡Adjusted for age, sex and body mass index 
§Competing risk model, adjusted for age, sex and body mass index 
 
